Black Diamond Therapeutics (BDTX) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

BDTX Stock Forecast


Black Diamond Therapeutics stock forecast is as follows: an average price target of $14.75 (represents a 393.31% upside from BDTX’s last price of $2.99) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

BDTX Price Target


The average price target for Black Diamond Therapeutics (BDTX) is $14.75 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $11.00. This represents a potential 393.31% upside from BDTX's last price of $2.99.

BDTX Analyst Ratings


Buy

According to 5 Wall Street analysts, Black Diamond Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for BDTX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Black Diamond Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 31, 2024Laura PrendergastRaymond James$20.00$5.91238.41%568.90%
Jun 03, 2024Joseph CalanzaroPiper Sandler$12.00$4.78150.84%301.34%
May 16, 2024Robert BurnsH.C. Wainwright$11.00$5.44102.21%267.89%
Apr 08, 2024Robert DriscollWedbush$16.00$5.06216.21%435.12%
Mar 18, 2024Raghuram SelvarajuH.C. Wainwright$12.00$4.70155.32%301.34%
Row per page
Go to

The latest Black Diamond Therapeutics stock forecast, released on Jul 31, 2024 by Laura Prendergast from Raymond James, set a price target of $20.00, which represents a 238.41% increase from the stock price at the time of the forecast ($5.91), and a 568.90% increase from BDTX last price ($2.99).

Black Diamond Therapeutics Price Target by Period


1M3M12M
# Anlaysts--5
Avg Price Target--$14.20
Last Closing Price$2.99$2.99$2.99
Upside/Downside-100.00%-100.00%374.92%

In the current month, the average price target of Black Diamond Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Black Diamond Therapeutics's last price of $2.99. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Sep 23, 2024Cowen & Co.BuyBuyHold
Sep 18, 2024H.C. WainwrightBuyBuyHold
Sep 10, 2024Piper SandlerOverweightOverweightHold
Jul 30, 2024Raymond James-OutperformInitialise
Jun 03, 2024Piper SandlerOverweightOverweightHold
May 16, 2024H.C. WainwrightBuyBuyHold
Apr 08, 2024WedbushOutperformOutperformHold
Jun 28, 2023H.C. Wainwright-BuyUpgrade
Jun 27, 2023Wedbush-OutperformUpgrade
Row per page
Go to

Black Diamond Therapeutics's last stock rating was published by Cowen & Co. on Sep 23, 2024. The company gave BDTX a "Buy" rating, the same as its previous rate.

Black Diamond Therapeutics Financial Forecast


Black Diamond Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

Black Diamond Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. BDTX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Black Diamond Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict BDTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Black Diamond Therapeutics's previous annual EBITDA (undefined) of $NaN.

Black Diamond Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-19.78M$-19.36M$-18.45M$-17.76M$-19.43M$-20.59M$-21.34M
High Forecast$-19.78M$-19.36M$-18.45M$-17.76M$-19.43M$-18.37M$-21.34M
Low Forecast$-19.78M$-19.36M$-18.45M$-17.76M$-19.43M$-22.82M$-21.34M
Surprise %-------

Black Diamond Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BDTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Black Diamond Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Black Diamond Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to BDTX last annual SG&A of $NaN (undefined).

Black Diamond Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-0.36$-0.35$-0.33$-0.32$-0.35$-0.37$-0.39
High Forecast$-0.36$-0.35$-0.33$-0.32$-0.35$-0.33$-0.39
Low Forecast$-0.36$-0.35$-0.33$-0.32$-0.35$-0.41$-0.39
Surprise %-------

According to undefined Wall Street analysts, Black Diamond Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BDTX previous annual EPS of $NaN (undefined).

Black Diamond Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BCELAtreca$0.09$4.004344.44%Buy
PASGPassage Bio$0.60$6.00900.00%Buy
BDTXBlack Diamond Therapeutics$2.99$14.75393.31%Buy
ADAPAdaptimmune Therapeutics$0.83$2.83240.96%Buy
FIXXQ32 Bio$0.93$2.70190.32%Buy
STOKStoke Therapeutics$13.10$30.60133.59%Buy
RVMDRevolution Medicines, Inc. Warrant$55.87$58.574.83%Buy

BDTX Forecast FAQ


Yes, according to 5 Wall Street analysts, Black Diamond Therapeutics (BDTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of BDTX's total ratings.

Black Diamond Therapeutics (BDTX) average price target is $14.75 with a range of $11 to $20, implying a 393.31% from its last price of $2.99. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for BDTX stock, the company can go up by 393.31% (from the last price of $2.99 to the average price target of $14.75), up by 568.90% based on the highest stock price target, and up by 267.89% based on the lowest stock price target.

BDTX's average twelve months analyst stock price target of $14.75 supports the claim that Black Diamond Therapeutics can reach $4 in the near future.

Black Diamond Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-61.364M (high $-59.138M, low $-63.59M), average SG&A $0 (high $0, low $0), and average EPS is $-1.113 (high $-1.072, low $-1.153). BDTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-75.349M (high $-75.349M, low $-75.349M), average SG&A $0 (high $0, low $0), and average EPS is $-1.366 (high $-1.366, low $-1.366).